Related content

Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now: Commentary to: 10.1007/s00415-010-5844-5 “One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients” by S. Malucchi et al.

By Menge Til   Hartung Hans-Peter   Kieseier Bernd  

Journal of Neurology, Vol. 258, Iss. 5, 2011-05 ,pp. : 904-907

Springer Publishing Company

Access to resources Recommend Favorite

Beta-interferon and multiple sclerosis

By Hall G.L.   Compston A.   Scolding N.J.  

Trends in Neurosciences, Vol. 20, Iss. 2, 1997-02 ,pp. : 63-67

Elsevier

Access to resources Recommend Favorite

Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients

By Garcia-Montojo Marta   Heras Virginia De Las   Bartolome Manuel   Arroyo Rafael   Alvarez-Lafuente Roberto  

Journal of NeuroVirology, Vol. 13, Iss. 6, 2007-11 ,pp. : 504-512

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis

By Ticha Veronika   Kalincik Tomas   Havrdova Eva  

Neurological Research, Vol. 34, Iss. 10, 2012-12 ,pp. : 923-930

Maney Publishing

Access to resources Recommend Favorite

Psoriasis during interferon beta treatment for multiple sclerosis

By La Mantia Loredana   Capsoni F.  

Neurological Sciences, Vol. 31, Iss. 3, 2010-06 ,pp. : 337-339

Springer Publishing Company

Access to resources Recommend Favorite